Results 21 to 30 of about 39,467 (264)

Bone Marrow Fibrosis in Chronic myeloid leukemia (CML) and other Myeloproliferative Disorders Evaluated by Using Special Histochemical Stains for Collagen.

مجلة كلية الطب, 2011
Background: It is still difficult to give a final diagnosis in chronic myeloproliferative disorders (CMPDs) because of the overlap of the common pathological and clinical features of these disorders like bone marrow fibrosis which is considered important
Ali Khalil I. Al-Khafaji, Haider H. Jaleel Al-Shammari, Salim R. Hamudi Al-Obeidi   +2 more
doaj   +1 more source

Erythematous Macular Eruption in an Older Woman [PDF]

, 2019
A white woman in her 70s with advanced Alzheimer disease was referred to the hematology clinic for evaluation of a high hemoglobin level (169 g/L; normal range, 120-160 g/L) and red blood cell count (5.67 × 1012/L; normal range, 3.8-4.8 × 1012/L) as well
Kernohan, Neil, McLaughlin, David, Tauro, Sudhir   +2 more
core   +2 more sources

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms [PDF]

, 2015
Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage genome-wide association study of 3,437 MPN cases and 10,
Aranaz, P., Aranaz, P., Bandinelli, S., Bandinelli, S., Barosi, G., Barosi, G., Baxter, E.J., Baxter, E.J., Callaway, A., Callaway, A., Campbell P., Campbell P., Cazzola, M., Cazzola, M., Chase, A., Chase, A., Chen, E., Chen, E., Cross N.C., Cross N.C., Dohner, K., Dohner, K., Duncombe, A.S., Duncombe, A.S., Evans, P., Evans, P., Ewing, J., Ewing, J., Gale, R.E., Gale, R.E., Giannopoulos, A., Giannopoulos, A., Gisslinger, H., Gisslinger, H., Godfrey, A.L., Godfrey, A.L., Grallert, H., Grallert, H., Green, A.R., Green, A.R., Griffiths, M., Griffiths, M., Guglielmelli, P., Guglielmelli, P., Haferlach, T., Haferlach, T., Harrison, C., Harrison, C., Harutyunyan, A.S., Harutyunyan, A.S., Jack, A., Jack, A., Jones, A.V., Jones, A.V., Kralovics, R., Kralovics, R., Leung, W., Leung, W., Lin, F., Lin, F., Maclean, C., Maclean, C., Mannarelli, C., Mannarelli, C., Mead, A.J., Mead, A.J., Nangalia, J., Nangalia, J., Oscier, D., Oscier, D., Pieri, L., Pieri, L., Reiter, A., Reiter, A., Schnittger, S., Schnittger, S., Schuh, A., Schuh, A., Short, M., Short, M., Stegelmann, F., Stegelmann, F., Strauch, K., Strauch, K., Tanaka, T., Tanaka, T., Tapper, W., Tapper, W., Vannucchi, A., Vannucchi, A., Waghorn, K., Waghorn, K., Wallis, L., Wallis, L., Ward, D., Ward, D., White, H.E., White, H.E., Zoi, K., Zoi, K.   +99 more
core   +5 more sources

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury

Haematologica, 2018
Myeloproliferative neoplasms are clonal stem cell disorders characterized by hematopoietic stem/progenitor cell expansion. The acquired kinase mutation JAK2V617F plays a central role in these disorders.
Chi Hua Sarah Lin, Yu Zhang, Kenneth Kaushansky, Huichun Zhan   +3 more
doaj   +1 more source

LNK (SH2B3): paradoxical effects in ovarian cancer. [PDF]

, 2015
LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined
Chien, W, Ding, L-W, Doan, NB, Dong, X-M, Garg, M, Gery, S, Hattori, N, Huang, RY-J, Koeffler, HP, Lin, D-C, Liu, L-Z, Meng, X, Said, JW, Sun, Q-Y, Tang, K, Xiao, J-F, Yang, H   +16 more
core   +2 more sources

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders

Haematologica, 2008
Background The JAK2 V617F mutation can be found in patients with polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis. Mutation or methylation of other components of JAK/STAT signaling, such as the negative regulators suppressor of ...
Nasios Fourouclas, Juan Li, Daniel C. Gilby, Peter J. Campbell, Philip A. Beer, Elaine M. Boyd, Anne C. Goodeve, David Bareford, Claire N. Harrison, John T. Reilly, Anthony R. Green, Anthony J. Bench   +11 more
doaj   +1 more source

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]

, 2018
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo, Barbui, Tiziano, Beggiato, Eloise, Bellini, Marta, Bertozzi, Irene, Betti, Silvia, Bonifacio, Massimiliano, Cacciola, Emma, Cacciola, Rossella, Carli, Giuseppe, Carobbio, Alessandra, Cattaneo, Daniele, Cazzola, Mario, Censori, Bruno, Cervantes, Francisco, Cortelezzi, Agostino, De Stefano, Valerio, Di Lazzaro, Vincenzo, Elli, Elena Maria, Ellis, Martin H., Finazzi, Guido, Finazzi, Maria Chiara, Gaidano, Gianluca, Gomez, Montse, Griesshammer, Martin, Guglielmelli, Paola, Hernandez-Boluda, Juan-Carlos, Iurlo, Alessandra, Loscocco, Giuseppe Gaetano, Lunghi, Francesca, Miroslava, Palova, Musolino, Caterina, Palandri, Francesca, Randi, Maria Luigia, Rapezzi, Davide, Rossi, Elena, Rumi, Elisa, Sadjadian, Parvis, Scaffidi, Luigi, Tieghi, Alessia, Vannucchi, Alessandro M., Vianelli, Nicola   +41 more
core   +5 more sources

A rare case of late myelodysplasia cutis associated with essential thrombocythemia: A case report

SAGE Open Medical Case Reports, 2022
Myelodysplasia cutis is a relatively new described entity that is characterized by cutaneous plaques and nodules representing dermal infiltration of myeloid immature non-blastic cells.
Suzel Fournier, Sylvain Mailhot, Janie Bujold   +2 more
doaj   +1 more source

Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease [PDF]

, 2016
Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable ...
How, Joan, Oh, Stephen T, Zhou, Amy
core   +2 more sources

Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

BMC Medical Genomics, 2019
Background Approximately 5–20% of chronic myeloid leukemia (CML) patients demonstrate primary resistance or intolerance to imatinib. None of the existing predictive scores gives a good prognosis of TKI efficacy.
Alexander V. Lavrov, Ekaterina Yu. Chelysheva, Elmira P. Adilgereeva, Oleg A. Shukhov, Svetlana A. Smirnikhina, Konstantin S. Kochergin-Nikitsky, Valentina D. Yakushina, Grigory A. Tsaur, Sergey V. Mordanov, Anna G. Turkina, Sergey I. Kutsev   +10 more
doaj   +1 more source